Clinical Research Directory
Browse clinical research sites, groups, and studies.
Probiotics Use and Preventing Gastrointestinal Symptoms in People Living With Overweight and Obesity.
Sponsor: University of Ulster
Summary
Inflammatory bowel disease (IBD) affects over 6.8 million people worldwide, with current treatments often causing side effects and poor patient compliance. Dysbiosis of gut microbiota is a key factor, and while probiotics are considered safe and beneficial, conventional strains fail to function effectively during active inflammation due to high iron levels in the gut. Streptococcus thermophilus (FX856), unlike traditional probiotics, can thrive in this iron-rich environment, promoting mucosal healing. A 2-way crossover intervention study will be conducted with FX856 supplementation in overweight and obese individuals who often exhibit mild gut inflammation by measuring faecal calprotectin and systemic inflammatory markers.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
100
Start Date
2025-10-14
Completion Date
2028-09-01
Last Updated
2025-11-28
Healthy Volunteers
Yes
Interventions
Probiotic Arm
1 x10\^9 cfu Streptococcus thermophilus (FX856), corn starch, anti-caking agent in a hydroxypropylmethycellulose \& pectin capsule.
Placebo Arm
corn starch, anti-caking agent in a hydroxypropylmethycellulose \& pectin capsule.
Locations (1)
Ulster University, Human Intervention Studies Unit
Coleraine, United Kingdom